Clinical Trial Update: Open Label, Multi-center, Phase I Study of TECLens Quantitative Refractive Crosslinking in Presbyopia-Aged Patients. [NA]

View source ↗

Summary

Open-label, multi-center Phase I study evaluating TECLens Quantitative Refractive Crosslinking for presbyopia. The trial is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• TECLens

Snippet

Sponsor: TECLens, Inc. | Conditions: Presbyopia | NA | Status: NOT_YET_RECRUITING